


Anti-SSTR Recombinant Antibody Products

Anti-SSTR Products
-
- Species Reactivity: Human
- Type: ADCC enhanced antibody
- Human Anti-SSTR Antibody, mRNA (TAB-584CL-mRNA)
-
- Species Reactivity: Human
- Anti-Human SSTR Recombinant Antibody (TAB-584CL)
-
- Species Reactivity: Human
- Type: Antibody
Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
For Research Use Only. Not For Clinical Use.
Creative Biolabs is pleased to introduce our comprehensive portfolio of anti-SSTR recombinant antibody products, meticulously developed to support and enhance the endeavors of researchers and pharmaceutical entities globally. Leveraging unparalleled scientific expertise and state-of-the-art technological platforms, these antibodies exhibit exceptional specificity and high affinity, thereby facilitating accelerated progress in critical investigations across diverse therapeutic and diagnostic domains worldwide. We invite you to explore how these innovative solutions can significantly augment your research initiatives.
SSTR: A Pivotal Target for Neuroendocrine Tumors
Somatostatin receptors (SSTRs) are a group of five G protein-coupled receptor subtypes (SSTR1-5) that control the various activities of somatostatin, a regulatory peptide hormone. These receptors are widely distributed throughout the body, influencing critical physiological processes such as hormone secretion, cell proliferation, neurotransmission, and immune modulation. Extensive research has highlighted their significant involvement in various pathological conditions, including neuroendocrine tumors, other cancers, inflammatory disorders, and metabolic diseases, making them crucial targets for novel therapeutic and diagnostic strategies.
Alternative Names
Somatostatin receptor; SSTR; SSTR1; SSTR2; SSTR3; SSTR4; SSTR5.
Background
The antibodies that specifically bind to the extracellular loop 2 (ecl2) of human somatostatin receptor (hSSTR) are used for diagnosing and treating various indications, including cancer and carcinoid syndrome.
Anti-SSTR rAb Products
Creative Biolabs' anti-SSTR recombinant antibody products are engineered with precision to provide exceptional performance. These antibodies boast high specificity and affinity for their respective SSTR subtypes, ensuring accurate detection and manipulation. Produced using advanced recombinant technology, they offer unparalleled batch-to-batch consistency and purity, minimizing experimental variability and accelerating your research breakthroughs in SSTR-related studies, from basic science to drug discovery.
Table 1. Featured anti-SSTR recombinant antibody products at Creative Biolabs.
Cat. No. | Product Name | Target Species | Host Species | Applications |
AFC-562CL | Afuco™ Anti-Human SSTR ADCC Recombinant Antibody, ADCC Enhanced | Human | Human ADCC Enhanced Antibody | |
TAB-584CL | Anti-Human SSTR Recombinant Antibody | Human | Human Antibody |
Creative Quality Control
At Creative Biolabs, every anti-SSTR recombinant antibody undergoes a stringent, multi-faceted quality control process. Our comprehensive testing includes ELISA, Western Blot, and flow cytometry to verify specificity and sensitivity. We also perform rigorous purity analysis and binding assays to ensure optimal performance and reproducibility, guaranteeing that our clients receive only the highest-grade reagents for their critical experiments.
Customer Reviews

Anti-Human SSTR Recombinant Antibody (TAB-584CL)

Afuco™ Anti-Human SSTR ADCC Recombinant Antibody, ADCC Enhanced (AFC-562CL)

Anti-Human SSTR Recombinant Antibody (TAB-584CL)
rAb Production
Our anti-SSTR recombinant antibody products are manufactured in-house using cutting-edge expression systems and purification techniques. This controlled environment ensures consistent quality and scalability. We utilize advanced bioreactor technology and optimized protocols to produce high yields of highly active and pure antibodies, meeting the diverse demands of both academic research and industrial applications with efficiency.
Featured Anti-SSTR Recombinant Antibody Production Platforms
Fig.1 Milligram-scale anti-SSTR recombinant antibody production.
Fig.2 Gram-scale anti-SSTR recombinant antibody production.
rAb Modalities
Our anti-SSTR recombinant antibody products are available in multiple modalities, offering versatile options for various experimental setups.
Fig.3 Full-length anti-SSTR recombinant antibody production and modalities.
SSTR-Targeted Drug Information
Table 2. Public drug targeting SSTR.
Company | Research phase | Classification | Condition |
Curium RadioMedix Rigshospitalet (Originator) University of Copenhagen (Originator) |
Launched - 2020 |
Copper Complexes Macrocyclic Peptides Nuclear Imaging Agents Octreotides Oligopeptides, less than 10 AA Peptide-Drug Conjugates Radiopharmaceuticals Somatostatin Analogues |
Neuroendocrine cancer |
Advanced Accelerator Applications Advanced Accelerator Applications (AAA) (Advanced Accelerator Applications) Göteborg University (Goeteborgs Universitet) IASON ITM Isotopen Technologien (ITM Isotope Technologies Munich) ITM Isotope Technologies Munich Jiangsu Hengrui Society Nuclear Medicine Mol Imaging Society of Nuclear Medicine Molec Im (Society Nuclear Medicine Mol Imaging) Universitaetsspitals Basel University of Iowa |
Launched - 2017 |
Gallium Complexes Macrocyclic Peptides Nuclear Imaging Agents Octreotides Oligopeptides, less than 10 AA Peptide-Drug Conjugates Radiopharmaceuticals Somatostatin Analogues |
Cancer Cancer, gastroenteropancreatic (neuroendocrine) Cancer, pituitary Neuroendocrine cancer |
Advanced Accelerator Applications Advanced Accelerator Applications (AAA) (Advanced Accelerator Applications) BioSynthema (Advanced Accelerator Applications) CanProbe FUJIFILM RI Pharma (FUJIFILM Toyama Chemical) FUJIFILM Toyama Chemical Medtronic (Originator) POINT Biopharma |
Launched - 2017 |
Lutetium Complexes Macrocyclic Peptides Octreotides Oligopeptides, less than 10 AA Peptide-Drug Conjugates Radionuclide Therapy Radiopharmaceuticals Somatostatin Analogues |
Cancer, breast Cancer, gastroenteropancreatic (neuroendocrine) Cancer, intestinal (neuroendocrine) Cancer, lung (small cell) (SCLC) (extensive) Cancer, pancreas (neuroendocrine) Glioblastoma Melanoma Meningioma Neuroendocrine cancer |
Advanced Accelerator Applications Advanced Accelerator Applications (AAA) (Advanced Accelerator Applications) E Kennedy Shriver NI Child Health Human National Cancer Institute RadioMedix |
Launched - 2016 |
Gallium Complexes Macrocyclic Peptides Nuclear Imaging Agents Octreotides Oligopeptides, less than 10 AA Peptide-Drug Conjugates Radiopharmaceuticals |
Cancer, gastroenteropancreatic (neuroendocrine) Cancer, liver (hepatocellular carcinoma) Cancer, prostate (castration-resistant), metastatic Cushing syndrome Neuroendocrine cancer Neurologic cancer Osteomalacia, oncogenic |
Amersham (GE Healthcare) Bayer (Originator) Berlex (Bayer) Cardinal Health CIS Bio International (Ion Beam Applications (IBA)) Diatide (Bayer) GE Healthcare Ion Beam Applications (IBA) |
Launched - 1999 |
Macrocyclic Peptides Nuclear Imaging Agents Peptide-Drug Conjugates Polypeptides, from 10 AA to 40 AA Radiopharmaceuticals Technetium Complexes |
Cancer Cancer, lung |
FUJIFILM RI Pharma (FUJIFILM Toyama Chemical) FUJIFILM Toyama Chemical Louisiana State University Mallinckrodt (Originator) Novartis (Originator) RadioMedix Takeda Tyco Healthcare Japan (Medtronic) |
Launched - 1994 |
Indium Complexes Macrocyclic Peptides Nuclear Imaging Agents Octreotides Oligopeptides, less than 10 AA Peptide-Drug Conjugates Radionuclide Therapy Radiopharmaceuticals Somatostatin Analogues |
Cancer Diagnostics Neuroendocrine cancer Sarcoidosis |
Universita di Bologna | Launched |
Gallium Complexes Macrocyclic Peptides Nuclear Imaging Agents Octreotides Oligopeptides, less than 10 AA Peptide-Drug Conjugates Radiopharmaceuticals |
Cancer |
Barts and the London NHS (Originator) Leopold-Franzens Universitaet Innsbruck (Originator) National Centre Nuclear Research Poland |
Launched |
Macrocyclic Peptides Nuclear Imaging Agents Octreotides Peptide-Drug Conjugates Polypeptides, from 10 AA to 40 AA Radiopharmaceuticals Technetium Complexes |
Neuroendocrine cancer |
All India Institute of Medical Sciences (Originator) RayzeBio |
Phase III |
Actinium Complexes Macrocyclic Peptides Octreotides Oligopeptides, less than 10 AA Peptide-Drug Conjugates Radionuclide Therapy Radiopharmaceuticals Somatostatin Analogues |
Cancer, gastroenteropancreatic (neuroendocrine) Cancer, lung (small cell) (SCLC) (extensive) Multiple myeloma |
DuChemBio ITG Isotope Technologies Garching (ITM Isotope Technologies Munich) ITM Isotopen Technologien (ITM Isotope Technologies Munich) ITM Isotope Technologies Munich RadioMedix Universitaetsspitals Basel (Originator) |
Phase III |
Lutetium Complexes Macrocyclic Peptides Octreotides Oligopeptides, less than 10 AA Peptide-Drug Conjugates Radionuclide Therapy Radiopharmaceuticals Somatostatin Analogues |
Cancer, gastroenteropancreatic (neuroendocrine) Cancer, solid tumor Neuroendocrine cancer |
Bayer (Originator) Ipsen |
Phase III |
Macrocyclic Peptides Nuclear Imaging Agents Oligopeptides, less than 10 AA Peptide-Drug Conjugates Radiopharmaceuticals Technetium Complexes |
Diagnostics |
(Disclaimer: The information in this table is just for knowledge sharing and not for marketing or sales purposes.)
At Creative Biolabs, we are dedicated to providing superior anti-SSTR recombinant antibody products that propel scientific discovery forward. Our dedication to quality and innovation guarantees that you have the greatest research tools available. Explore our complete catalogue and get in touch with us right now to discuss your individual project requirements and learn how our experience may help you achieve your next breakthrough.